[SCHEDULE 13G] CytomX Therapeutics, Inc. SEC Filing
OrbiMed Advisors LLC reported beneficial ownership of 8,461,500 shares of CytomX Therapeutics common stock, representing 5.4% of the class. The Schedule 13G filing states OrbiMed has shared voting and dispositive power over all reported shares and no sole voting or dispositive power. The filing identifies the reporting person as an investment adviser organized in Delaware and confirms these shares are held on behalf of other persons. The filing includes a certification that the position was not acquired to change or influence control of the issuer.
OrbiMed Advisors LLC ha dichiarato la propriet脿 beneficiaria di 8.461.500 azioni ordinarie di CytomX Therapeutics, pari al 5,4% della classe. La comunicazione Schedule 13G indica che OrbiMed detiene potere di voto e dispositivi condivisi su tutte le azioni riportate e nessun potere di voto o dispositivo esclusivo. La nota identifica la parte che presenta la dichiarazione come un consulente di investimento costituito nel Delaware e conferma che queste azioni sono detenute per conto di terzi. La dichiarazione include inoltre una certificazione che la posizione non 猫 stata acquisita per modificare o influenzare il controllo dell鈥檈mittente.
OrbiMed Advisors LLC inform贸 la propiedad beneficiaria de 8.461.500 acciones ordinarias de CytomX Therapeutics, que representan el 5,4% de la clase. la presentaci贸n Schedule 13G se帽ala que OrbiMed tiene poderes de voto y dispositivos compartidos sobre todas las acciones notificadas y ning煤n poder exclusivo de voto o dispositvo. El documento identifica al informante como un asesor de inversiones constituido en Delaware y confirma que estas acciones se mantienen en nombre de otras personas. Tambi茅n incluye una certificaci贸n de que la posici贸n no se adquiri贸 para cambiar o influir en el control del emisor.
OrbiMed Advisors LLC電� CytomX Therapeutics 氤错喌欤� 8,461,500欤�(頃措嫻 韥措灅鞀れ潣 5.4%)鞐� 雽�頃� 鞁れ唽鞙犼秾鞚� 氤搓碃頄堨姷雼堧嫟. Schedule 13G 鞝滌稖靹滌棎 霐半ゴ氅� OrbiMed電� 氤搓碃霅� 氇摖 欤检嫕鞐� 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓�鞚� 氤挫湢頃橁碃 鞛堨溂氅� 雼弲 鞚橁舶甓� 霕愲姅 觳橂秳甓岇潃 鞐嗠嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滌棎電� 氤搓碃鞚胳潉 雿鸽澕鞗柎鞐� 靹る霅� 韴瀽 鞛愲須岇偓搿� 鞁濍硠頃橂┌ 鞚� 欤检嫕霌れ澊 雼るジ 靷瀸霌れ潉 雽�鞁犿暣 氤挫湢霅橁碃 鞛堨潓鞚� 頇曥澑頃╇媹雼�. 霕愴暅 頃措嫻 歆�攵勳澊 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橁赴 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 鞚胳頃橂姅 雮挫毄鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
OrbiMed Advisors LLC a d茅clar茅 la propri茅t茅 b茅n茅ficiaire de 8 461 500 actions ordinaires de CytomX Therapeutics, soit 5,4 % de la cat茅gorie. Le d茅p么t Schedule 13G indique qu鈥橭rbiMed d茅tient des pouvoirs de vote et de disposition partag茅s sur toutes les actions d茅clar茅es et aucun pouvoir de vote ou de disposition exclusif. Le document identifie le d茅clarant comme un conseiller en investissement constitu茅 dans le Delaware et confirme que ces actions sont d茅tenues pour le compte de tiers. Il comprend 茅galement une attestation pr茅cisant que la position n鈥檃 pas 茅t茅 acquise dans le but de modifier ou d鈥檌nfluencer le contr么le de l鈥櫭﹎etteur.
OrbiMed Advisors LLC meldete wirtschaftliches Eigentum an 8.461.500 Aktien der Stammaktien von CytomX Therapeutics, was 5,4% der Klasse entspricht. Die Schedule-13G-Einreichung besagt, dass OrbiMed 眉ber alle gemeldeten Aktien geteilte Stimm- und Verf眉gungsbefugnisse hat und keine alleinigen Stimm- oder Verf眉gungsbefugnisse besitzt. Die Meldung f眉hrt die meldende Partei als in Delaware gegr眉ndeten Anlageberater auf und best盲tigt, dass diese Aktien im Auftrag anderer Personen gehalten werden. Weiterhin enth盲lt die Einreichung eine Best盲tigung, dass die Position nicht erworben wurde, um die Kontrolle 眉ber den Emittenten zu 盲ndern oder zu beeinflussen.
- OrbiMed Advisors LLC disclosed a beneficial ownership stake of 8,461,500 shares
- The reported stake represents 5.4% of CytomX Therapeutics' common stock, exceeding the 5% reporting threshold
- Filing certifies the position is not held to change or influence control of the issuer
- None.
Insights
TL;DR: OrbiMed holds a disclosed 5.4% stake with shared voting power; filing is a routine, material ownership disclosure.
OrbiMed Advisors LLC reports beneficial ownership of 8,461,500 common shares (5.4%), with shared voting and dispositive power and no sole control. The Schedule 13G classification and the certifying statement indicate the position is reported as passive under applicable rules rather than an intent to control. For investors, this is a material ownership disclosure because it crosses the 5% threshold that triggers public reporting requirements, but the filing contains no information about changes in holdings, transactions, or strategic plans.
TL;DR: This is a standard passive investor disclosure showing institutional presence but no stated control intent.
The filing designates OrbiMed Advisors LLC as the reporting person and notes shared voting and disposition rights exercised through a management committee. The filing explicitly states the shares are held on behalf of others and includes a certification that the stake was not acquired to influence control. There are no governance actions, board nominations, or group affiliations disclosed here. As such, the filing signals institutional ownership without immediate governance implications.
OrbiMed Advisors LLC ha dichiarato la propriet脿 beneficiaria di 8.461.500 azioni ordinarie di CytomX Therapeutics, pari al 5,4% della classe. La comunicazione Schedule 13G indica che OrbiMed detiene potere di voto e dispositivi condivisi su tutte le azioni riportate e nessun potere di voto o dispositivo esclusivo. La nota identifica la parte che presenta la dichiarazione come un consulente di investimento costituito nel Delaware e conferma che queste azioni sono detenute per conto di terzi. La dichiarazione include inoltre una certificazione che la posizione non 猫 stata acquisita per modificare o influenzare il controllo dell鈥檈mittente.
OrbiMed Advisors LLC inform贸 la propiedad beneficiaria de 8.461.500 acciones ordinarias de CytomX Therapeutics, que representan el 5,4% de la clase. la presentaci贸n Schedule 13G se帽ala que OrbiMed tiene poderes de voto y dispositivos compartidos sobre todas las acciones notificadas y ning煤n poder exclusivo de voto o dispositvo. El documento identifica al informante como un asesor de inversiones constituido en Delaware y confirma que estas acciones se mantienen en nombre de otras personas. Tambi茅n incluye una certificaci贸n de que la posici贸n no se adquiri贸 para cambiar o influir en el control del emisor.
OrbiMed Advisors LLC電� CytomX Therapeutics 氤错喌欤� 8,461,500欤�(頃措嫻 韥措灅鞀れ潣 5.4%)鞐� 雽�頃� 鞁れ唽鞙犼秾鞚� 氤搓碃頄堨姷雼堧嫟. Schedule 13G 鞝滌稖靹滌棎 霐半ゴ氅� OrbiMed電� 氤搓碃霅� 氇摖 欤检嫕鞐� 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓�鞚� 氤挫湢頃橁碃 鞛堨溂氅� 雼弲 鞚橁舶甓� 霕愲姅 觳橂秳甓岇潃 鞐嗠嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滌棎電� 氤搓碃鞚胳潉 雿鸽澕鞗柎鞐� 靹る霅� 韴瀽 鞛愲須岇偓搿� 鞁濍硠頃橂┌ 鞚� 欤检嫕霌れ澊 雼るジ 靷瀸霌れ潉 雽�鞁犿暣 氤挫湢霅橁碃 鞛堨潓鞚� 頇曥澑頃╇媹雼�. 霕愴暅 頃措嫻 歆�攵勳澊 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橁赴 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 鞚胳頃橂姅 雮挫毄鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
OrbiMed Advisors LLC a d茅clar茅 la propri茅t茅 b茅n茅ficiaire de 8 461 500 actions ordinaires de CytomX Therapeutics, soit 5,4 % de la cat茅gorie. Le d茅p么t Schedule 13G indique qu鈥橭rbiMed d茅tient des pouvoirs de vote et de disposition partag茅s sur toutes les actions d茅clar茅es et aucun pouvoir de vote ou de disposition exclusif. Le document identifie le d茅clarant comme un conseiller en investissement constitu茅 dans le Delaware et confirme que ces actions sont d茅tenues pour le compte de tiers. Il comprend 茅galement une attestation pr茅cisant que la position n鈥檃 pas 茅t茅 acquise dans le but de modifier ou d鈥檌nfluencer le contr么le de l鈥櫭﹎etteur.
OrbiMed Advisors LLC meldete wirtschaftliches Eigentum an 8.461.500 Aktien der Stammaktien von CytomX Therapeutics, was 5,4% der Klasse entspricht. Die Schedule-13G-Einreichung besagt, dass OrbiMed 眉ber alle gemeldeten Aktien geteilte Stimm- und Verf眉gungsbefugnisse hat und keine alleinigen Stimm- oder Verf眉gungsbefugnisse besitzt. Die Meldung f眉hrt die meldende Partei als in Delaware gegr眉ndeten Anlageberater auf und best盲tigt, dass diese Aktien im Auftrag anderer Personen gehalten werden. Weiterhin enth盲lt die Einreichung eine Best盲tigung, dass die Position nicht erworben wurde, um die Kontrolle 眉ber den Emittenten zu 盲ndern oder zu beeinflussen.
FAQ
What stake did OrbiMed Advisors LLC report in CytomX (CTMX)?
Does OrbiMed have sole voting or dispositive power over the CTMX shares?
Was the position reported as intended to influence control of CytomX?
Who exercises the reported investment and voting power on behalf of OrbiMed?
What is the filing form and date for this disclosure?
